Intellia therapeutics reports inducement grants under nasdaq listing rule 5635(c)(4)

Cambridge, mass., dec. 03, 2024 (globe newswire) -- intellia therapeutics, inc. (nasdaq:ntla), a leading clinical-stage gene editing company focused on revolutionizing medicine with crispr-based therapies, today announced that on december 1, 2024, it awarded an inducement grant to one new employee under intellia's 2024 inducement plan as a material inducement to employment.
NDAQ Ratings Summary
NDAQ Quant Ranking